ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -5 مورد

Carfilzomib: Drug information

Carfilzomib: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Carfilzomib: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Kyprolis
Brand Names: Canada
  • Kyprolis
Pharmacologic Category
  • Antineoplastic Agent, Proteasome Inhibitor
Dosing: Adult

Dosage guidance:

Safety: Adequate hydration with oral fluids (30 mL/kg at least 48 hours prior to cycle 1, day 1) and IV fluids (250 to 500 mL of appropriate solution before each dose in cycle 1) is necessary prior to cycle 1, particularly in patients at risk for tumor lysis syndrome or renal toxicity. If needed, administer an additional 250 to 500 mL of appropriate IV fluid after carfilzomib administration; continue oral and/or IV hydration in subsequent cycles if necessary. Adjust hydration based on individual needs. Premedication may be required to reduce the incidence and severity of infusion reactions (Ref).

Dosing: Calculate carfilzomib dose using actual BSA. Patients with a BSA >2.2 m2 should be dosed using a BSA of 2.2 m2. Dose adjustments for weight changes of ≤20% are not necessary (Ref).

Clinical considerations: Consider antiviral prophylaxis to decrease the risk of herpes zoster reactivation. Provide thromboprophylaxis when administering in combination with other therapies per institutional and clinical practice guidelines based on underlying risk factors. Control/optimize hypertension prior to initiating carfilzomib (Ref).

Heart transplantation, desensitization

Heart transplantation, desensitization (adjunctive) (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.

IV: 20 mg/m2 for 6 doses administered on days 1, 2, 8, 9, 15, and 16; cycle may be repeated until clinical endpoints achieved (Ref). Escalating doses up to 36 mg/m2/dose were used in a single case after inadequate response to the initial cycle (Ref).

Kidney transplantation, desensitization

Kidney transplantation, desensitization (adjunctive) (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.

IV: 20 mg/m2/day on days 1 and 2; then 27 mg/m2/day on days 8, 9, 15, and 16; then 36 mg/m2/day on days 29, 30, 36, 37, 43, and 44 (total of 12 doses) (Ref).

Lung transplantation, antibody-mediated rejection, treatment

Lung transplantation, antibody-mediated rejection, treatment (adjunctive) (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.

IV: 20 mg/m2 administered over 10 to 30 minutes for 6 doses administered on days 1, 2, 8, 9, 15, and 16 (Ref).

Multiple myeloma, newly diagnosed

Multiple myeloma, newly diagnosed (off-label use):

Note: Consider antihyperuricemic agents in patients at risk for tumor lysis syndrome. Premedicate with dexamethasone orally or IV at least 30 minutes to 4 hours prior to all doses in cycle 1 to reduce the incidence and severity of infusion reactions; resume dexamethasone premedication if symptoms occur in subsequent cycles. When using carfilzomib in combination, premedicate with the recommended dexamethasone dose defined as part of the combination therapy (refer to protocol). If carfilzomib is administered as a single agent, premedicate with dexamethasone 4 mg (10-minute infusion) or 8 mg (30-minute infusion) orally or IV in cycle 1 and as needed thereafter to minimize infusion-related reactions (Ref).

Multiple myeloma, newly diagnosed, in combination with cyclophosphamide and dexamethasone; 20/36 mg/m2 twice-weekly regimen (adults ≥65 years or ineligible for autologous transplant):

Cycle 1: IV: 20 mg/m2 over 30 minutes on days 1 and 2, and 36 mg/m2 over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (in combination with cyclophosphamide and dexamethasone) (Ref).

Cycles 2 to 9: IV: 36 mg/m2 over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle (in combination with cyclophosphamide and dexamethasone) (Ref).

Cycles 10 and beyond (maintenance): IV: 36 mg/m2 on days 1, 2, 15, and 16 of a 28-day treatment cycle (as a single-agent) until disease progression or unacceptable toxicity (Ref).

Multiple myeloma, newly diagnosed, in combination with lenalidomide, daratumumab, and dexamethasone; 20/56 mg/m2 once-weekly regimen (in the absence of autologous transplant):

Cycle 1: IV: 20 mg/m2 over 30 minutes on day 2, and 56 mg/m2 over 30 minutes on days 8 and 15 of a 28-day treatment cycle (in combination with lenalidomide, dexamethasone, and daratumumab) (Ref).

Cycles 2 to 8: IV: 56 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day treatment cycle (in combination with lenalidomide, dexamethasone, and daratumumab) (Ref).

Multiple myeloma, relapsed or refractory

Multiple myeloma, relapsed or refractory:

Note: Consider antihyperuricemic agents in patients at risk for tumor lysis syndrome. Premedicate with dexamethasone orally or IV at least 30 minutes to 4 hours prior to all doses in cycle 1 to reduce the incidence and severity of infusion reactions; resume dexamethasone premedication if symptoms occur in subsequent cycles. When using carfilzomib in combination, premedicate with the recommended dexamethasone dose defined as part of the combination therapy (refer to protocol). If carfilzomib is administered as a single agent, premedicate with dexamethasone 4 mg (10-minute infusion) or 8 mg (30-minute infusion) orally or IV in cycle 1 and as needed thereafter to minimize infusion-related reactions (Ref).

Multiple myeloma, relapsed or refractory, single-agent; 20/27 mg/m2 twice-weekly regimen:

Cycle 1: IV: 20 mg/m2 over 10 minutes on days 1 and 2; if tolerated, increase dose to 27 mg/m2 over 10 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle.

Cycles 2 to 12: IV: 27 mg/m2 over 10 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle.

Cycle 13 and beyond: IV: 27 mg/m2 over 10 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.

Note: In a randomized study, 12 cycles of the 20/27 mg/m2 regimen were compared to the 20/56 mg/m2 regimen (both administered in combination with dexamethasone); while there was no significant difference in response rates or progression-free survival, the 20/27 mg/m2 regimen was associated with a statistically significantly lower incidence of peripheral neuropathy, thrombocytopenia, and fatigue (Ref).

Multiple myeloma, relapsed or refractory, single-agent; 20/56 mg/m2 twice-weekly regimen:

Cycle 1: IV: 20 mg/m2 over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m2 over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle.

Cycles 2 to 12: IV: 56 mg/m2 over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle.

Cycle 13 and beyond: IV: 56 mg/m2 over 30 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.

Multiple myeloma, relapsed or refractory, in combination with lenalidomide and dexamethasone; 20/27 mg/m2 twice-weekly regimen (KRd regimen):

Cycle 1: IV: 20 mg/m2 over 10 minutes on days 1 and 2; if tolerated, increase dose to 27 mg/m2 over 10 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (Ref).

Cycles 2 to 12: IV: 27 mg/m2 over 10 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle (Ref).

Cycles 13 to 18: IV: 27 mg/m2 over 10 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; discontinue carfilzomib after cycle 18; beginning with cycle 19, lenalidomide and dexamethasone may be continued until disease progression or unacceptable toxicity (Ref).

Multiple myeloma, relapsed or refractory, in combination with dexamethasone; 20/56 mg/m2 twice-weekly regimen:

Cycle 1: IV: 20 mg/m2 over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m2 over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (Ref).

Cycle 2 and beyond: IV: 56 mg/m2 over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (Ref).

Multiple myeloma, relapsed or refractory, in combination with dexamethasone; 20/70 mg/m2 once-weekly regimen:

Cycle 1: IV: 20 mg/m2 over 30 minutes on day 1; increase dose to 70 mg/m2 over 30 minutes on days 8 and 15 of a 28-day treatment cycle (Ref).

Cycle 2 and beyond: IV: 70 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (Ref).

Multiple myeloma, relapsed or refractory, in combination with daratumumab and dexamethasone or daratumumab/hyaluronidase and dexamethasone; 20/56 mg/m2 twice-weekly regimen (DKd regimen):

Cycle 1: IV: 20 mg/m2 over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m2 over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (Ref).

Cycles 2 and beyond: IV: 56 mg/m2 over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (Ref).

Multiple myeloma, relapsed or refractory, in combination with daratumumab and dexamethasone or daratumumab/hyaluronidase and dexamethasone; 20/70 mg/m2 once-weekly regimen (DKd regimen):

Cycle 1: IV: 20 mg/m2 over 30 minutes on day 1; if tolerated, increase dose to 70 mg/m2 over 30 minutes on days 8 and 15 of a 28-day treatment cycle (Ref).

Cycles 2 and beyond: IV: 70 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (Ref).

Multiple myeloma, relapsed or refractory, in combination with isatuximab and dexamethasone; 20/56 mg/m2 twice-weekly regimen (IsaKd regimen):

Cycle 1: IV: 20 mg/m2 over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m2 over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (Ref).

Cycles 2 and beyond: IV: 56 mg/m2 over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (Ref).

Multiple myeloma, relapsed or refractory, in combination with pomalidomide and dexamethasone (off-label combination); 20/27 mg/m2 once-weekly regimen (KPd regimen):

Cycle 1: IV: 20 mg/m2 over 10 minutes on day 1; if tolerated, increase dose to 27 mg/m2 over 10 minutes on days 8 and 15 of a 28-day treatment cycle (Ref).

Cycles 2 to 8: IV: 27 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day treatment cycle (Ref).

Cycles 9 and beyond (maintenance): IV: 27 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (Ref). Refer to protocol for further information.

Multiple myeloma, relapsed or refractory, in combination with pomalidomide and dexamethasone (off-label combination); 20/27 mg/m2 twice-weekly regimen (KPd regimen):

Cycle 1: IV: 20 mg/m2 over 30 minutes on days 1 and 2; if tolerated, increase dose to 27 mg/m2 over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (Ref).

Cycles 2 to 6: IV: 27 mg/m2 over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle (Ref).

Cycles 7 and beyond (maintenance): IV: 27 mg/m2 over 30 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (Ref). Refer to protocol for further information.

Waldenström macroglobulinemia

Waldenström macroglobulinemia (CaRD regimen) (off-label use):

Note: Consider antihyperuricemic agents in patients at risk for tumor lysis syndrome. When using carfilzomib in combination, premedicate with the recommended dexamethasone dose defined as part of the combination therapy (refer to protocol).

Induction:

Cycle 1: IV: 20 mg/m2 over 20 minutes on days 1, 2, 8, and 9 of a 21-day treatment cycle (in combination with dexamethasone and rituximab) (Ref).

Cycles 2 to 6: IV: 36 mg/m2 over 30 minutes on days 1, 2, 8, and 9 of a 21-day treatment cycle (in combination with dexamethasone and rituximab) (Ref).

Maintenance (started 8 weeks after completion of induction therapy in patients with stable disease or better response): IV: 36 mg/m2 on days 1 and 2 every 8 weeks for 8 cycles (in combination with dexamethasone and rituximab) (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Kidney impairment prior to treatment initiation:

Note: During treatment, monitor serum creatinine and kidney function closely; new-onset acute kidney injury or severe kidney dysfunction may occur in carfilzomib-treated patients. One population-based study observed a rate of new-onset kidney failure as high as 22%. In addition, case reports of thrombotic microangiopathy have been described with use (Ref).

Altered kidney function: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzable (high protein binding): No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzable (Ref): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment likely to be necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment likely to be necessary (Ref).

Kidney toxicity during treatment: Serum creatinine ≥2 times baseline, CrCl <15 mL/minute or CrCl decreases to ≤50% of baseline, or patient requires hemodialysis: Withhold dose and monitor kidney function. If renal toxicity is due to carfilzomib, resume dosing when kidney function has improved to within 25% of baseline; resume with a reduced dose by 1 dose level (see "Dosing: Adjustment for Toxicity" for dose level reductions). If toxicity is not due to carfilzomib, restart at the discretion of the prescriber.

Dosing: Liver Impairment: Adult

Hepatic impairment prior to treatment initiation:

Mild (total bilirubin 1 to 1.5 times ULN and any AST or total bilirubin ≤ULN and AST >ULN) or moderate (total bilirubin >1.5 to 3 times ULN and any AST) impairment: Reduce carfilzomib dose by 25%.

Severe (bilirubin > 3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer's labeling (a recommended dose has not been in established in patients with bilirubin >3 times ULN and any AST).

Hepatotoxicity during treatment: Grade 3 or 4 elevation of bilirubin, transaminases, or other liver abnormalities: Withhold dose until resolved or at baseline. After resolution, if appropriate to reinitiate, consider restarting at 1 dose level reduction (see Dosing: Adjustment for Toxicity for dose level reductions) with frequent monitoring of hepatic function.

Dosing: Obesity: Adult

ASCO Guidelines for appropriate chemotherapy dosing in adults with a BMI ≥30 kg/m2 with cancer: In general, utilize patient's actual body weight for calculation of BSA- or weight-based dosing, manage regimen-related toxicities in the same manner as for patients with a BMI <30 kg/m2; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or renal impairment) are sufficiently resolved AND if performance status has markedly improved or is considered adequate (Ref). Note: According to the manufacturer, patients with a BSA >2.2 m2 should be dosed based upon a maximum BSA of 2.2 m2; dose adjustments for weight changes of ≤20% are not necessary.

Dosing: Adjustment for Toxicity: Adult

Carfilzomib dose level reductions for toxicity:

Carfilzomib Dose Level Reductions in Relapsed or Refractory Multiple Myelomaa

Regimen

Usual dose

First dose reduction

Second dose reduction

Third dose reduction

a Infusion times remain unchanged during dose reduction(s). Concomitant combination anticancer therapies may also require dosage modification; refer to those monographs for dosage adjustment recommendations.

b If toxicity persists, discontinue carfilzomib treatment.

Carfilzomib, lenalidomide, and dexamethasone; or carfilzomib monotherapy (twice weekly)

27 mg/m2

20 mg/m2

15 mg/m2 b

Carfilzomib and dexamethasone; or carfilzomib, daratumumab or daratumumab/hyaluronidase, and dexamethasone; or carfilzomib, isatuximab, and dexamethasone; or carfilzomib monotherapy (twice weekly)

56 mg/m2

45 mg/m2

36 mg/m2

27 mg/m2 b

Carfilzomib and dexamethasone; or carfilzomib, daratumumab or daratumumab/hyaluronidase, and dexamethasone (once weekly)

70 mg/m2

56 mg/m2

45 mg/m2

36 mg/m2 b

Carfilzomib Recommended Dosage Adjustments for Adverse Reactions in Relapsed or Refractory Multiple Myelomaa

Adverse reaction

Severity

Carfilzomib dosage modification

a PRES = posterior reversible encephalopathy syndrome; TTP/HUS = thrombocytopenic thrombotic purpura/hemolytic uremic syndrome

Hematologic toxicity

Neutropenia

ANC <500/mm3

Withhold carfilzomib dose until ANC recovers to ≥500/mm3; resume at the same dose level.

For subsequent ANC levels <500/mm3, withhold carfilzomib dose until ANC ≥500/mm3; consider reducing dose by 1 dose level when resuming carfilzomib.

Neutropenic fever

ANC <500/mm3 with an oral temperature >38.5°C or 2 consecutive readings of >38°C for 2 hours

Withhold carfilzomib dose; if ANC recovers to baseline and fever resolves, resume at the same dose level.

Thrombocytopenia

Platelets <10,000/mm3 or evidence of bleeding with thrombocytopenia

Withhold carfilzomib dose until platelets recover to ≥10,000/mm3 and/or bleeding is controlled; resume at the same dose level.

For subsequent platelet levels <10,000/mm3, withhold carfilzomib dose until platelets ≥10,000/mm3; consider reducing dose by 1 dose level when resuming carfilzomib.

Nonhematologic toxicity

Cardiotoxicity

Grade 3 or 4, new-onset or worsening of heart failure, decreased left ventricular function, or myocardial ischemia

Withhold carfilzomib dose until resolved or at baseline. After resolution, if considered appropriate to reinitiate, consider restarting at 1 dose level reduction.

Hemorrhage or symptoms of blood loss

Any

Reduce carfilzomib dose or withhold treatment as clinically appropriate.

Hypertension

Severe or life-threatening

If hypertension cannot be adequately controlled, withhold carfilzomib dose and evaluate. After resolution, consider if appropriate to reinitiate based on risk versus benefit.

PRES

Suspected

Discontinue carfilzomib if PRES diagnosis is suspected; the safety of reinitiating therapy after PRES diagnosis is not known.

Progressive multifocal leukoencephalopathy

Suspected

Discontinue carfilzomib if progressive multifocal leukoencephalopathy is suspected; refer to a neurologist.

Pulmonary toxicity

Drug-induced acute respiratory distress syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease (eg, pneumonitis or interstitial lung disease)

Discontinue carfilzomib.

Pulmonary hypertension

Withhold carfilzomib dose until resolved or at baseline. Perform cardiac imaging or other testing as appropriate. After resolution, consider if appropriate to reinitiate based on risk versus benefit.

Grade 3 or 4 dyspnea

Withhold carfilzomib dose until resolved or at baseline. After resolution, consider if appropriate to reinitiate based on risk versus benefit.

Thrombotic microangiopathy

Suspected

Interrupt carfilzomib and manage appropriately if thrombotic microangiopathy, including TTP/HUS diagnosis is suspected. If TTP/HUS diagnosis is excluded, may consider reinitiating therapy; the safety of restarting carfilzomib after a TTP/HUS diagnosis is not known.

Tumor lysis syndrome

Uncontrolled

Interrupt carfilzomib treatment and manage promptly until resolved.

Other nonhematologic adverse reactions

Grade 3 or 4

Withhold carfilzomib dose until resolved or at baseline. After resolution, consider restarting the next scheduled treatment at 1 dose level reduction.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported from monotherapy studies in adults.

>10%:

Cardiovascular: Cardiac arrhythmia (13%) (Siegel 2013), chest pain (3% to 21%), hypertension (15% to 42%; including hypertensive crisis), peripheral edema (20% to 21%)

Endocrine & metabolic: Hypokalemia (14%) (Siegel 2013), hypomagnesemia (14%) (Siegel 2013)

Gastrointestinal: Constipation (11%) (Siegel 2013), decreased appetite (15% to 21%), diarrhea (25% to 27%; grades ≥3: 1% to 4%), nausea (35% to 54%; grades ≥3: 1%), vomiting (17% to 33%; grades ≥3: 1%)

Hematologic & oncologic: Anemia (42% to 49%; grades ≥3: 24% to 29%), leukopenia (11%; grade 3/4: 5%) (Siegel 2013), lymphocytopenia (14% to 33%; grades ≥3: 12% to 33%), neutropenia (16%; grade 3/4: 18%) (Siegel 2013), thrombocytopenia (37% to 54%; grades ≥3: 25% to 54%)

Nervous system: Chills (12% to 38%), dizziness (11% to 29%), fatigue (40% to 58%), headache (24% to 33%), insomnia (13% to 29%), peripheral neuropathy (≤19%; including dysesthesia, hypoesthesia, neuralgia, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy) (Siegel 2013)

Neuromuscular & skeletal: Back pain (19% to 21%), muscle spasm (10% to 21%)

Renal: Increased serum creatinine (17% to 25%), renal insufficiency (13%) (Siegel 2013)

Respiratory: Cough (22% to 33%), dyspnea (34% to 58%), upper respiratory tract infection (19% to 21%)

Miscellaneous: Fever (30% to 58%)

1% to 10%:

Cardiovascular: Cardiomyopathy (2%) (Siegel 2013), heart failure (7%) (Siegel 2013), ischemic heart disease (3%) (Siegel 2013), venous thromboembolism (2%; including deep vein thrombosis and pulmonary embolism)

Endocrine & metabolic: Hypercalcemia (grades ≥3: 4%) (Siegel 2013), hyperglycemia (grades ≥3: ≤4%), hyperkalemia (grades ≥3: ≤4%), hypocalcemia (grades ≥3: ≤4%), hyponatremia (grades ≥3: 7%) (Siegel 2013), hypophosphatemia (grades ≥3: 5%) (Siegel 2013)

Hematologic & oncologic: Febrile neutropenia (1%) (Seigel 2013)

Renal: Acute kidney injury (5%), renal failure syndrome (4%) (Siegel 2013)

Respiratory: Pleural effusion (4%) (Siegel 2013), pneumonia (8%), pulmonary hypertension (2%) (Siegel 2013)

<1%:

Hematologic & oncologic: Tumor lysis syndrome (Siegel 2013)

Respiratory: Hemoptysis (Siegel 2013), pneumonitis (Siegel 2013)

Frequency not defined:

Cardiovascular: Acute myocardial infarction, hypotension, reduced ejection fraction, thromboembolic complications

Dermatologic: Erythema of skin, hyperhidrosis, pruritus, skin rash

Endocrine & metabolic: Hyperuricemia, hypoalbuminemia

Gastrointestinal: Abdominal pain, dyspepsia, toothache, upper abdominal pain

Genitourinary: Urinary tract infection

Hematologic & oncologic: Hemorrhage (including epistaxis, gastrointestinal hemorrhage, intracranial hemorrhage, pulmonary hemorrhage)

Hepatic: Hepatic failure, increased serum transaminases (including increased serum alanine aminotransferase and increased serum aspartate aminotransferase) (Siegel 2013)

Hypersensitivity: Infusion-related reaction

Infection: Influenza, sepsis

Local: Infusion-site reaction

Nervous system: Anxiety, asthenia, pain, voice disorder

Neuromuscular & skeletal: Arthralgia, limb pain, musculoskeletal chest pain, musculoskeletal pain, myalgia

Ophthalmic: Blurred vision, cataract

Otic: Tinnitus

Respiratory: Acute respiratory distress syndrome, acute respiratory failure, bronchitis, bronchopneumonia, nasopharyngitis, oropharyngeal pain, pulmonary disease (acute diffuse infiltrative, including interstitial pulmonary disease), pulmonary edema, pulmonary infection, respiratory tract infection, rhinitis

Miscellaneous: Multi-organ failure

Postmarketing (may include combination therapy):

Cardiovascular: Pericarditis

Gastrointestinal: Acute pancreatitis, enterocolitis, gastrointestinal perforation, intestinal obstruction

Hematologic & oncologic: Hemolytic-uremic syndrome, thrombotic microangiopathy, thrombotic thrombocytopenic purpura

Infection: Cytomegalovirus disease, reactivation of HBV, viremia

Nervous system: Progressive multifocal leukoencephalopathy, reversible posterior leukoencephalopathy syndrome

Ophthalmic: Chorioretinitis

Contraindications

There are no contraindications listed in the manufacturer's US labeling.

Canadian labeling: Hypersensitivity to carfilzomib or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Thrombocytopenia (including grade 4) was observed in patients receiving carfilzomib, with platelet nadirs occurring between day 8 and day 15 of each 28-day treatment cycle and recovery to baseline by the start of the next cycle. Hemorrhage due to thrombocytopenia may occur.

• Cardiovascular effects: Carfilzomib has been associated with new-onset or worsening of heart failure, pulmonary edema, decreased ejection fraction, cardiomyopathy, myocardial ischemia, and myocardial infarction (MI) (including fatalities). Some events occurred in patients with normal ventricular function at baseline. Cardiac events typically were observed throughout the course of therapy. Death caused by cardiac arrest has occurred within 1 day of carfilzomib administration. Patients ≥75 years of age have an increased risk of heart failure. Patients with NYHA class III and IV heart failure, recent MI (within 3 to 6 months), and conduction abnormalities, angina, or arrhythmias not managed by medication were excluded from clinical trials and may be at increased risk for cardiac complications; evaluate with a comprehensive medical assessment prior to initiation and closely monitor.

• Hemorrhage: Serious or fatal cases of hemorrhage have been reported, including GI, intracranial, and pulmonary hemorrhage and epistaxis. Bleeding may be spontaneous; intracranial hemorrhage has occurred without trauma. Hemorrhage has been reported in patients with normal or low platelet counts and has also been reported in patients who were not receiving anticoagulation or antiplatelet therapy.

• Hepatic effects: Hepatic failure, including fatal cases, has been reported rarely. Increased transaminases and hyperbilirubinemia have also been observed.

• Hypertension: Hypertension has occurred with carfilzomib; hypertensive crisis and hypertensive emergency have also been reported (some events were fatal).

• Infusion-related reactions: May occur immediately following or within 24 hours of carfilzomib infusion; may be life-threatening. Signs/symptoms have included fever, chills, arthralgia, myalgia, flushing, facial or laryngeal edema, vomiting, weakness, dyspnea, hypotension, syncope, chest tightness, or angina.

• Kidney toxicity: Renal insufficiency, acute kidney failure, and kidney failure have been reported with carfilzomib; some events have been fatal. Acute kidney failure was observed more frequently in patients receiving carfilzomib monotherapy for advanced relapsed or refractory multiple myeloma; kidney failure risk is greater when patients have a baseline reduced CrCl.

• Posterior reversible encephalopathy syndrome: Posterior reversible encephalopathy syndrome (PRES) has been reported rarely with use; symptoms include seizure, headache, lethargy, confusion, blindness, altered consciousness, hypertension, and other visual/neurological disturbances.

• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML), which may be fatal, has been reported; prior or concurrent immunosuppressive therapy may be a contributory factor. Consider PML with new-onset or changes in preexisting neurological signs or symptoms.

• Pulmonary toxicities: Acute respiratory distress syndrome (ARDS), acute respiratory failure, and acute diffuse-infiltrative pulmonary disease (eg, pneumonitis and interstitial lung disease) have occurred in a small percentage of patients (some events were fatal). In clinical trials, pulmonary arterial hypertension (PAH) was observed (including grade 3 or higher events). Dyspnea (including grade 3 or higher events) has been reported.

• Thrombotic microangiopathy: Thrombotic microangiopathy, including cases of thrombocytopenic thrombotic purpura/hemolytic uremic syndrome (TTP/HUS), has been reported (some fatal).

• Thromboembolic events: Venous thromboembolism (eg, deep vein thrombosis and pulmonary embolism) has been observed, particularly when used as part of combination therapy with dexamethasone or with lenalidomide plus dexamethasone.

• Tumor lysis syndrome: Tumor lysis syndrome (TLS), including fatalities, has been observed. TLS risk is increased in multiple myeloma patients with a high tumor burden.

Disease-related concerns:

• Hepatic impairment: The incidence of serious adverse events is higher in patients with mild, moderate, and severe baseline hepatic impairment combined (compared to patients with normal hepatic function).

Concurrent drug therapy issues:

• Combination therapy toxicity: An increased incidence of serious and fatal adverse events was observed in a clinical trial comparing the combination of carfilzomib, melphalan, and prednisone (KMP) to bortezomib, melphalan, and prednisone (VMP) for the treatment of newly diagnosed multiple myeloma (MM) in transplant-ineligible patients. Cardiac failure, hypertension, acute kidney failure, and dyspnea were observed more frequently in the KMP arm. KMP is not an approved carfilzomib combination regimen.

Special populations:

• Older adult: The incidence of serious adverse events is higher in patients ≥65 years of age (compared to patients <65 years of age).

Dosage form specific issues:

• Excipient: Carfilzomib contains the excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin), which may accumulate in patients with renal insufficiency, although the clinical significance of this finding is uncertain (Luke 2010).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous:

Kyprolis: 10 mg (1 ea); 30 mg (1 ea); 60 mg (1 ea)

Generic Equivalent Available: US

No

Pricing: US

Solution (reconstituted) (Kyprolis Intravenous)

10 mg (per each): $707.44

30 mg (per each): $2,122.32

60 mg (per each): $4,244.63

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous:

Kyprolis: 10 mg (1 ea); 30 mg (1 ea); 60 mg (1 ea)

Administration: Adult

IV: Administer over 10 or 30 minutes depending on the carfilzomib dose regimen. Do not administer as an IV push or bolus. Hydrate with oral fluids (30 mL/kg) at least 48 hours prior to initiating cycle 1, as well as with 250 to 500 mL NS (or other appropriate IV fluid) prior to (recommended) and after (if needed) each dose in cycle 1; continue oral and/or IV hydration in subsequent cycles (if necessary). Flush line immediately before and after carfilzomib with NS or D5W. Do not administer with other medications.

When administering as monotherapy, premedicate with dexamethasone 4 mg orally or IV when infusing carfilzomib over 10 minutes or with dexamethasone 8 mg orally or IV when infusing carfilzomib over 30 minutes. When using combination therapy, administer the recommended dexamethasone dose (refer to prescribing information). Premedicate 30 minutes to 4 hours prior to all carfilzomib doses in cycle 1, and as needed with future cycles to reduce the incidence and severity of infusion reaction.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2024 [table 2]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2023; NIOSH 2024; USP-NF 2020).

Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.

Use: Labeled Indications

Multiple myeloma, relapsed or refractory:

Treatment (as a single agent) of relapsed or refractory multiple myeloma in adults who have received 1 or more lines of therapy.

Treatment of relapsed or refractory multiple myeloma (in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, or with daratumumab/hyaluronidase plus dexamethasone, or with isatuximab plus dexamethasone) in adults who have received 1 to 3 prior lines of therapy.

Use: Off-Label: Adult

Heart transplantation, desensitization; Kidney transplantation, desensitization; Lung transplantation, antibody-mediated rejection, treatment; Multiple myeloma, newly diagnosed; Waldenström macroglobulinemia

Medication Safety Issues
Sound-alike/look-alike issues:

Carfilzomib may be confused with bortezomib, ixazomib

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (chemotherapeutic agent, parenteral and oral) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care, Community/Ambulatory Care, and Long-Term Care Settings).

Metabolism/Transport Effects

Substrate of P-glycoprotein (Minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Abrocitinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Androgens: Hypertension-Associated Agents may increase hypertensive effects of Androgens. Risk C: Monitor

Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor

Antithyroid Agents: Myelosuppressive Agents may increase neutropenic effects of Antithyroid Agents. Risk C: Monitor

Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Baricitinib. Risk X: Avoid

BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of BCG Products. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Brincidofovir. Risk C: Monitor

Brivudine: May increase adverse/toxic effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Chikungunya Vaccine (Live). Risk X: Avoid

Chloramphenicol (Ophthalmic): May increase adverse/toxic effects of Myelosuppressive Agents. Risk C: Monitor

Chloramphenicol (Systemic): Myelosuppressive Agents may increase myelosuppressive effects of Chloramphenicol (Systemic). Risk X: Avoid

Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Cladribine. Risk X: Avoid

CloZAPine: Myelosuppressive Agents may increase adverse/toxic effects of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor

Coccidioides immitis Skin Test: Coadministration of Immunosuppressants (Miscellaneous Oncologic Agents) and Coccidioides immitis Skin Test may alter diagnostic results. Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor

COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (Subunit). Risk C: Monitor

Deferiprone: Myelosuppressive Agents may increase neutropenic effects of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider Therapy Modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Dengue Tetravalent Vaccine (Live). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Denosumab: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections. Risk D: Consider Therapy Modification

Deucravacitinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Etrasimod: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Fexinidazole: Myelosuppressive Agents may increase myelosuppressive effects of Fexinidazole. Risk X: Avoid

Filgotinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Hormonal Contraceptives: May increase thrombogenic effects of Carfilzomib. Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib, especially patients using carfilzomib in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone. Risk D: Consider Therapy Modification

Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Inebilizumab. Risk C: Monitor

Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored. Risk D: Consider Therapy Modification

Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents. Risk D: Consider Therapy Modification

Linezolid: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Mumps- Rubella- or Varicella-Containing Live Vaccines may increase adverse/toxic effects of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid

Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Natalizumab. Risk X: Avoid

Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ocrelizumab. Risk C: Monitor

Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ofatumumab. Risk C: Monitor

Olaparib: Myelosuppressive Agents may increase myelosuppressive effects of Olaparib. Risk C: Monitor

Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Pidotimod. Risk C: Monitor

Pimecrolimus: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Pneumococcal Vaccines. Risk C: Monitor

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may increase hypersensitivity effects of Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider Therapy Modification

Promazine: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider Therapy Modification

Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ritlecitinib. Risk X: Avoid

Ropeginterferon Alfa-2b: Myelosuppressive Agents may increase myelosuppressive effects of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider Therapy Modification

Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ruxolitinib (Topical). Risk X: Avoid

Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider Therapy Modification

Solriamfetol: May increase hypertensive effects of Hypertension-Associated Agents. Risk C: Monitor

Sphingosine 1-Phosphate (S1P) Receptor Modulators: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk C: Monitor

Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Tacrolimus (Topical). Risk X: Avoid

Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid

Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Tertomotide. Risk X: Avoid

Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Tofacitinib. Risk X: Avoid

Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Typhoid Vaccine. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ublituximab. Risk C: Monitor

Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Upadacitinib. Risk X: Avoid

Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Vaccines (Live). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Vaccines (Non-Live/Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Vaccines (Non-Live/Inactivated/Non-Replicating). Management: Give non-live/inactivated/non-replicating vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before or during therapy should be revaccinated at least 3 months after therapy is complete. Risk D: Consider Therapy Modification

Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Yellow Fever Vaccine. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Zoster Vaccine (Live/Attenuated): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Zoster Vaccine (Live/Attenuated). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Zoster Vaccine (Live/Attenuated). Risk X: Avoid

Reproductive Considerations

Conduct pregnancy testing prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should avoid pregnancy during carfilzomib treatment and use effective contraception during treatment and for 6 months after the last carfilzomib dose. Due to risk of thrombosis with hormonal contraception, consider an alternative method of effective contraception during combination treatment of carfilzomib with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.

Patients with partners who could become pregnant should use effective contraception during treatment and for 3 months after the last carfilzomib dose.

Carfilzomib may impair fertility in males and females (based on the mechanism of action).

Pregnancy Considerations

Based on the mechanism of action and findings from animal reproduction studies, in utero exposure to carfilzomib may cause fetal harm.

Breastfeeding Considerations

It is not known if carfilzomib is present in breast milk.

Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during carfilzomib treatment and for 2 weeks after the last dose of carfilzomib.

Monitoring Parameters

CBC with differential and platelets (monitor frequently throughout therapy), serum potassium levels regularly during treatment, kidney function, pulmonary function (with new or worsening pulmonary symptoms), LFTs (regularly), BP (regularly throughout treatment in all patients). Pregnancy test (prior to treatment initiation) in patients who could become pregnant. Monitor for signs/symptoms of infusion-related reactions, congestive heart failure, hemorrhage (promptly evaluate symptoms of blood loss), tumor lysis syndrome, peripheral neuropathy, posterior reversible encephalopathy syndrome, progressive multifocal leukoencephalopathy, thrombocytopenic thrombotic purpura/hemolytic uremic syndrome, and venous thromboembolic events. Monitor closely for cardiac complications and evidence of volume overload due to pre- and post-hydration, particularly in patients at risk for heart failure.

The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow up.

Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017], (ESC [Lyon 2022]). Assess BP at baseline and each clinical visit (also consider weekly home monitoring for initial 3 months, then monthly thereafter); assess natriuretic peptide at baseline for high and very high-risk patients and consider at each cycle for the first 6 cycles; consider checking natriuretic peptide at baseline for low- and moderate-risk patients; obtain a baseline echocardiography in all patients; repeat echocardiography every 3 cycles in high- and very-high risk patients and consider echocardiography every 3 cycles in low- and moderate-risk patients (ESC [Lyon 2022]).

Mechanism of Action

Carfilzomib inhibits proteasomes, which are responsible for intracellular protein homeostasis. Specifically, it is a potent, selective, and irreversible inhibitor of chymotrypsin-like activity of the 20S proteasome, leading to cell cycle arrest and apoptosis.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vdss: 28 L (based on a 20 mg/m2 dose); penetrates all tissues extensively except the brain (Kortuem 2013).

Protein binding: 97%; to human plasma proteins.

Metabolism: Rapidly metabolized; primarily via peptidase cleavage and epoxide hydrolysis; minimal metabolism through cytochrome P450-mediated mechanisms.

Half-life elimination: Doses ≥15 mg/m2: ≤1 hour on day 1 of cycle 1.

Excretion: Urine (~25% as metabolites; <1% as parent drug); feces (<1% as parent drug).

Clearance: 151 to 263 L/hour.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Patients with end-stage kidney disease requiring hemodialysis had a 33% higher AUC compared to patients with normal kidney function.

Hepatic function impairment: Patients with mild (total bilirubin 1 to 1.5 times ULN and any AST or total bilirubin ≤ULN and AST >ULN) or moderate (bilirubin >1.5 to 3 times ULN and any AST) hepatic impairment had an approximately 50% higher AUC compared to patients with normal hepatic function.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Kyprolis;
  • (AR) Argentina: Alcaf | Calefir | Carfizol | Filzocar | Karfib | Kyprolis | Seutig | Tsumis;
  • (AT) Austria: Kyprolis;
  • (AU) Australia: Kyprolis;
  • (BE) Belgium: Kyprolis;
  • (BG) Bulgaria: Kyprolis;
  • (BR) Brazil: Kyprolis;
  • (CH) Switzerland: Kyprolis;
  • (CL) Chile: Alcaf;
  • (CO) Colombia: Kyprolis | Xafilred;
  • (CZ) Czech Republic: Kyprolis;
  • (DE) Germany: Kyprolis;
  • (EC) Ecuador: Alcaf | Filzocar | Karfib | Kyprolis;
  • (EE) Estonia: Kyprolis;
  • (ES) Spain: Kyprolis;
  • (FI) Finland: Kyprolis;
  • (FR) France: Kyprolis;
  • (GB) United Kingdom: Kyprolis;
  • (GR) Greece: Kyprolis;
  • (HK) Hong Kong: Kyprolis;
  • (HR) Croatia: Kyprolis;
  • (HU) Hungary: Kyprolis;
  • (IE) Ireland: Kyprolis;
  • (IN) India: Carfilnat | Carfizome | Carzomib | Zucarfil;
  • (IT) Italy: Kyprolis;
  • (JP) Japan: Kyprolis;
  • (KR) Korea, Republic of: Kyprolis;
  • (KW) Kuwait: Kyprolis;
  • (LB) Lebanon: Kyprolis;
  • (LT) Lithuania: Kyprolis;
  • (LV) Latvia: Kyprolis;
  • (MA) Morocco: Kyprolis;
  • (MX) Mexico: Kyprolis;
  • (MY) Malaysia: Kyprolis;
  • (NL) Netherlands: Kyprolis;
  • (NO) Norway: Kyprolis;
  • (NZ) New Zealand: Kyprolis;
  • (PL) Poland: Kyprolis;
  • (PR) Puerto Rico: Kyprolis;
  • (PT) Portugal: Kyprolis;
  • (QA) Qatar: Kyprolis;
  • (RO) Romania: Kyprolis;
  • (RU) Russian Federation: Kyprolis;
  • (SA) Saudi Arabia: Kyprolis;
  • (SE) Sweden: Kyprolis;
  • (SG) Singapore: Kyprolis;
  • (SI) Slovenia: Kyprolis;
  • (SK) Slovakia: Kyprolis;
  • (TH) Thailand: Kyprolis;
  • (TR) Turkey: Kyprolis;
  • (TW) Taiwan: Kyprolis;
  • (ZA) South Africa: Kyprolis
  1. Ailawadhi S, Sexton R, Lentzsch S, et al. Low-dose versus high-dose carfilzomib with dexamethasone (S1304) in patients with relapsed-refractory multiple myeloma. Clin Cancer Res. 2020;26(15):3969-3978. doi:10.1158/1078-0432.CCR-19-1997 [PubMed 32299820]
  2. Alishetti S, Farr M, Jennings D, et al. Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. Am J Transplant. 2020;20(12):3620-3630. doi:10.1111/ajt.16113 [PubMed 32506824]
  3. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893-911. [PubMed 27918725]
  4. Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27(8):1707-1714. [PubMed 23364621]
  5. Bringhen S, Mina R, Cafro AM, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia. 2018;32(8):1803-1807. doi:10.1038/s41375-018-0024-1 [PubMed 29479061]
  6. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69. doi: 10.1182/blood-2014-03-563759. [PubMed 24855212]
  7. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020;7(11):e827-e837. doi:10.1016/S2352-3026(20)30224-6 [PubMed 33091356]
  8. Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(5):421-431. doi:10.1182/blood.2019000722 [PubMed 31113777]
  9. Colvin MM, Cook JL, Chang PP, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Cardiovascular Surgery and Anesthesia. Sensitization in heart transplantation: Emerging knowledge: A scientific statement from the American Heart Association. Circulation. 2019;139(12):e553-e578. doi:10.1161/CIR.0000000000000598 [PubMed 30776902]
  10. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186-197. doi:10.1016/S0140-6736(20)30734-0 [PubMed 32682484]
  11. Dimopoulos MA, Moreau P, Palumbo A, et al; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study. Lancet Oncol. 2016a;17(1):27-38. [PubMed 26671818]
  12. Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016b;34(13):1544-1557. [PubMed 26976420]
  13. Ensor CR, Yousem SA, Marrari M, et al. Proteasome inhibitor carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings. Am J Transplant. 2017;17(5):1380-1388. doi:10.1111/ajt.14222 [PubMed 28173620]
  14. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  15. Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471 [PubMed 33939491]
  16. Hodson L, Ovesen J, Couch J, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Managing hazardous drug exposures: information for healthcare settings, 2023. https://doi.org/10.26616/NIOSHPUB2023130. Updated April 2023. Accessed December 27, 2024.
  17. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757 [PubMed 32716741]
  18. Jhaveri KD, Chidella S, Varghese J, Mailloux L, Devoe C. Carfilzomib-related acute kidney injury. Clin Adv Hematol Oncol. 2013;11(9):604-605. [PubMed 24518527]
  19. Kortuem KM and Stewart AK. Carfilzomib. Blood. 2013;121(6):893-897. [PubMed 23393020]
  20. Kwon D, Niesvizky R. Treatment of multiple myeloma with carfilzomib in patients with renal injury. Clin Adv Hematol Oncol. 2013;11(9):605-606. [PubMed 24518528]
  21. Kyprolis (carfilzomib) [prescribing information]. Thousand Oaks, CA: Onyx Pharmaceuticals Inc; June 2022.
  22. Kyprolis (carfilzomib) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; July 2023.
  23. Landgren O, Hultcrantz M, Diamond B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7(6):862-868. doi:10.1001/jamaoncol.2021.0611 [PubMed 33856405]
  24. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016;128(10):1321-1328. [PubMed 27432877]
  25. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291-3301. [PubMed 20213839]
  26. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244 [PubMed 36017568]
  27. Mian HS, Fiala MA, Sanchez L, Vij R, Wildes TM. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world". Ann Hematol. 2021;100(5):1261-1266. doi:10.1007/s00277-021-04420-3 [PubMed 33475778]
  28. Moreau P, Chari A, Haenel M, et al. Subcutaneous daratumumab (DARA SC) plus standard-of-care (SoC) regimens in multiple myeloma (MM) across lines of therapy in the phase 2 pleiades study: initial results of the DARA SC plus carfilzomib/dexamethasone (D-Kd) cohort, and updated results for the DARA SC plus bortezomib/melphalan/prednisone (D-VMP) and DARA SC plus lenalidomide/dexamethasone (D-Rd) cohorts. Blood. 2020;136(suppl 1):28-30. https://ashpublications.org/blood/article/136/Supplement%201/28/471077/Subcutaneous-Daratumumab-DARA-SC-Plus-Standard-of. Accessed December 8, 2021.
  29. Moreau P, Dimopoulos MA, Mikhael J, et al; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. doi:10.1016/S0140-6736(21)00592-4 [PubMed 34097854]
  30. Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study [published correction appears in Lancet Oncol. 2018;19(8):e382]. Lancet Oncol. 2018;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. [PubMed 29866475]
  31. Ovesen JL, Sammons D, Connor TH, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2024. https://doi.org/10.26616/NIOSHPUB2025103. Updated December 18, 2024. Accessed December 20, 2024.
  32. Papadopoulos KP, Siegel DS, Vesole DH, et al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015;33(7):732-739. doi: 10.1200/JCO.2013.52.3522. [PubMed 25225420]
  33. Pham C, Pierce BJ, Nguyen DT, Graviss EA, Huang HJ. Assessment of carfilzomib treatment response in lung transplant recipients with antibody-mediated rejection. Transplant Direct. 2021;7(4):e680. doi:10.1097/TXD.0000000000001131 [PubMed 33748409]
  34. Philipponnet C, Aniort J, Atenza A, Heng AE, Souweine B. Carfilzomib induced microangiopathy due to accumulation with paxlovid. Kidney Int Rep. 2022;7(12):2746-2749. doi:10.1016/j.ekir.2022.09.006 [PubMed 36506224]
  35. Pratt G, El-Sharkawi D, Kothari J, et al; Diagnosis and management of Waldenström macroglobulinaemia-a British Society for Haematology guideline. Br J Haematol. 2022;197(2):171-187. doi:10.1111/bjh.18036 [PubMed 35020191]
  36. Quach H, White D, Spencer A, et al. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemother Pharmacol. 2017;79(6):1067-1076. [PubMed 28424963]
  37. Rassner M, Baur R, Wäsch R, et al. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with eculizumab in multiple myeloma. BMC Nephrol. 2021;22(1):32. doi:10.1186/s12882-020-02226-5 [PubMed 33461512]
  38. Razia D, Hu C, Cherrier L, Nasar A, Walia R, Tokman S. Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients. Transpl Immunol. 2022;75:101703. doi:10.1016/j.trim.2022.101703 [PubMed 36049718]
  39. Refer to manufacturer's labeling.
  40. Richter J, Biran N, Duma N, Vesole DH, Siegel D. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series. Hematol Oncol. 2017;35(2):246-251. doi:10.1002/hon.2290 [PubMed 27018162]
  41. Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126(20):2284-2290. doi:10.1182/blood-2015-05-643320 [PubMed 26384354]
  42. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753-1761. [PubMed 23935022]
  43. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817-2825. doi:10.1182/blood-2012-05-425934 [PubMed 22833546]
  44. Sriwattanakomen R, Xu Q, Demehin M, et al. Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates. J Heart Lung Transplant. 2021;40(7):595-603. doi:10.1016/j.healun.2021.03.001 [PubMed 33785250]
  45. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152. [PubMed 25482145]
  46. Tremblay S, Driscoll JJ, Rike-Shields A, et al. A prospective, iterative, adaptive trial of carfilzomib-based desensitization. Am J Transplant. 2020;20(2):411-421. doi:10.1111/ajt.15613 [PubMed 31550069]
  47. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014;124(4):503-510. doi:10.1182/blood-2014-03-566273 [PubMed 24859363]
  48. United States Pharmacopeia. <800> Hazardous Drugs—Handling in Healthcare Settings. In: USP-NF. United States Pharmacopeia; July 1, 2020. Accessed January 16, 2025. doi:10.31003/USPNF_M7808_07_01
  49. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015 [PubMed 37080658]
  50. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012; 119(24):5661-5670. [PubMed 22555973]
Topic 86042 Version 293.0